GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocera Therapeutics Inc (NAS:OCRX) » Definitions » ROA %

Ocera Therapeutics (Ocera Therapeutics) ROA % : -134.55% (As of Sep. 2017)


View and export this data going back to 2011. Start your Free Trial

What is Ocera Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Ocera Therapeutics's annualized Net Income for the quarter that ended in Sep. 2017 was $-25.08 Mil. Ocera Therapeutics's average Total Assets over the quarter that ended in Sep. 2017 was $18.64 Mil. Therefore, Ocera Therapeutics's annualized ROA % for the quarter that ended in Sep. 2017 was -134.55%.

The historical rank and industry rank for Ocera Therapeutics's ROA % or its related term are showing as below:

OCRX's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -35.42
* Ranked among companies with meaningful ROA % only.

Ocera Therapeutics ROA % Historical Data

The historical data trend for Ocera Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocera Therapeutics ROA % Chart

Ocera Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
ROA %
Get a 7-Day Free Trial Premium Member Only -15.31 -64.59 -44.67 -54.24 -72.32

Ocera Therapeutics Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.81 -64.85 -95.08 -101.63 -134.55

Competitive Comparison of Ocera Therapeutics's ROA %

For the Biotechnology subindustry, Ocera Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocera Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocera Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Ocera Therapeutics's ROA % falls into.



Ocera Therapeutics ROA % Calculation

Ocera Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2016 is calculated as:

ROA %=Net Income (A: Dec. 2016 )/( (Total Assets (A: Dec. 2015 )+Total Assets (A: Dec. 2016 ))/ count )
=-26.895/( (44.737+29.639)/ 2 )
=-26.895/37.188
=-72.32 %

Ocera Therapeutics's annualized ROA % for the quarter that ended in Sep. 2017 is calculated as:

ROA %=Net Income (Q: Sep. 2017 )/( (Total Assets (Q: Jun. 2017 )+Total Assets (Q: Sep. 2017 ))/ count )
=-25.076/( (21.684+15.589)/ 2 )
=-25.076/18.6365
=-134.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2017) net income data. ROA % is displayed in the 30-year financial page.


Ocera Therapeutics  (NAS:OCRX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2017 )
=Net Income/Total Assets
=-25.076/18.6365
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-25.076 / 0)*(0 / 18.6365)
=Net Margin %*Asset Turnover
=N/A %*0
=-134.55 %

Note: The Net Income data used here is four times the quarterly (Sep. 2017) net income data. The Revenue data used here is four times the quarterly (Sep. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Ocera Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Ocera Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocera Therapeutics (Ocera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
525 University Avenue, Suite 610, Palo Alto, CA, USA, 94301
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company, which primarily targets acute and chronic orphan liver diseases. The company is focused on the development and commercialization of a clinical product candidate, OCR-002 for the treatment of acute and chronic hepatic encephalopathy for patients with a serious complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. All the business activity of the firm is functioned through the region of US.
Executives
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Kim P. Kamdar 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Associates Domain 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Domain Partners Vi, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner

Ocera Therapeutics (Ocera Therapeutics) Headlines

From GuruFocus

Top 3 Insider Buys of the Week

By Monica Wolfe Monica Wolfe 07-19-2013

Three Insider Buys at 52-Week Lows

By Monica Wolfe Monica Wolfe 07-22-2014